Perindopril in Breast Milk and Determination of Breastfed Infant Exposure: A Prospective Observational Study
Files
(Published version)
Date
2020
Authors
Leggett, C.
Lwin, E.M.P.
Ritchie, U.
Song, Y.
Gerber, J.P.
Turner, S.
Hague, W.M.
Stark, M.
Upton, R.
Garg, S.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Drug Design, Development and Therapy, 2020; 14:961-967
Statement of Responsibility
Catherine Leggett, Ei Mon Phyo Lwin, Usha Ritchie, Yunmei Song, Jacobus P Gerber, Sean Turner, William M Hague, Michael Stark, Richard Upton, Sanjay Garg
Conference Name
Abstract
Objective: This study aimed to quantify the amount of perindopril and its active metabolite perindoprilat present in breast milk and corresponding maternal and infant plasma concentrations. Design: Prospective, longitudinal, observational. Setting: Tertiary specialist paediatric and obstetric hospital in Adelaide, South Australia. Population: Breastfeeding women actively treated with perindopril for hypertensive disorders postpartum. Methods: Eight breast milk samples and a single plasma sample were collected from each participant over a 24 hrs period, and plasma samples were taken from eligible breastfed infants. Breast milk and plasma concentrations of perindopril and perindoprilat were analysed using a validated Liquid Chromatography tandem-Mass Spectrometry (LC-MS/MS) method. Main Outcome Measures: Mean breast milk concentrations of perindopril and perindoprilat, Relative Infant Dose (RID) <10%, and Theoretical Infant Dose (TID). Results: Ten women and three infants participated in the study. The mean concentration of perindopril in breast milk for each participant ranged from 0.003 to 1.2 ng/mL and perindoprilat 0.2–36 ng/mL. RID for perindopril was 0.0005–0.2% and perindoprilat 0.03–4.6%. TID for perindopril was 0.00045–0.18 μg/kg/day and perindoprilat 0.032–5.4 μg/kg/day. Infant plasma levels for perindopril ranged from 0.44 to 1.12 ng/mL and perindoprilat undetectable – 10.14 ng/mL. Maternal reports described normal infant growth and development. Conclusion: Infant exposure to perindopril and perindoprilat through breast milk is low. However, some infants were found to have plasma perindoprilat concentrations consistent with pharmacodynamic effects. Perindopril may be used in mothers of healthy term infants, provided the infant is carefully monitored.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2020 Leggett et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).